virologic response

(MedPage Today) -- A combination of direct-acting antiviral agents aimed at hepatitis C -- and given without standard therapy -- can lead to sustained virologic response in patients with a difficult-to-treat strain of the virus.

(MedPage Today) -- Combining traditional therapy for HCV infection with the newly approved drug telaprevir (Incivek) and an investigational oral HCV polymerase inhibitor boosted 24-week complete virologic response rates to 90% in a phase II study, the drugs' manufacturer said.

Hepatitis C (HCV) therapy based on low-dose peginterferon alpha-2b (Peg-Intron) achieved a sustained virologic response rate and tolerability comparable to a higher dose of alpha-2b and peginterferon alpha-2a (Pegasys), investigators in a large multicenter clinical trial reported.

CHICAGO (MedPage Today) -- The investigational protease inhibitor telaprevir, added to standard hepatitis C (HCV) treatment, produced a sustained virologic response in about half of patients who had previously failed with conventional therapy, a phase IIb trial showed.